Janssen’s HIV Regimen Earns Funding From NHS England
NHS England agreed to offer Janssen’s combination HIV-1 treatment Symtuza through the national health service.
Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), which is taken without other antiretroviral medicines, is for patients who have not received anti-HIV-1 medicines in the past and who require a darunavir-based single tablet regimen.
The once-daily regimen is for adults and adolescents aged 12 years and older with a body weight of at least 40 kilograms (88.2 pounds).
The FDA approved Symtuza in July.